Skye Bioscience, Inc. financial data

Symbol
SKYE on Nasdaq
Industry
Pharmaceutical Preparations
Location
11250 El Camino Real, Suite 100, San Diego, CA
State of incorporation
NV
Fiscal year end
December 31
Former names
Emerald Bioscience, Inc. (to 1/7/2021), Nemus Bioscience, Inc. (to 3/14/2019), LOAD GUARD LOGISTICS, INC. (to 10/30/2014), LOAD GUARD TRANSPORTATION, INC. (to 11/7/2012)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 829 % +1065%
Debt-to-equity 13.8 %
Return On Equity -35.9 % -103%
Return On Assets -31.6 % +92.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31M shares +10.4%
Common Stock, Shares, Outstanding 31M shares +151%
Entity Public Float 225M USD +1002%
Common Stock, Value, Issued 31K USD +151%
Weighted Average Number of Shares Outstanding, Basic 36.5M shares +421%
Weighted Average Number of Shares Outstanding, Diluted 36.5M shares +421%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.29M USD +52.2%
General and Administrative Expense 17.7M USD +126%
Operating Income (Loss) -30.2M USD +13.1%
Nonoperating Income (Expense) 3.64M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -26.6M USD +29.4%
Income Tax Expense (Benefit) 10.1K USD +180%
Net Income (Loss) Attributable to Parent -26.6M USD +29.4%
Earnings Per Share, Basic -0.73 USD/shares +86.4%
Earnings Per Share, Diluted -0.73 USD/shares +86.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68.4M USD +5345%
Cash, Cash Equivalents, and Short-term Investments 0 USD
Other Assets, Current 2.21M USD +97.3%
Assets, Current 70.8M USD +508%
Property, Plant and Equipment, Net 1.43M USD +3211%
Operating Lease, Right-of-Use Asset 450K USD +89%
Other Assets, Noncurrent 53.9K USD +549%
Assets 72.8M USD +509%
Accounts Payable, Current 780K USD -52.2%
Employee-related Liabilities, Current 1.11M USD +25.4%
Liabilities, Current 4.34M USD -68.8%
Operating Lease, Liability, Noncurrent 273K USD +59.5%
Liabilities 4.61M USD -67.2%
Retained Earnings (Accumulated Deficit) -131M USD -25.5%
Stockholders' Equity Attributable to Parent 68.2M USD
Liabilities and Equity 72.8M USD +509%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.71M USD -15.9%
Net Cash Provided by (Used in) Financing Activities 85.7M USD
Net Cash Provided by (Used in) Investing Activities 1.14M USD -79.4%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 31M shares +151%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 82.1M USD +5664%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68.4M USD +562%
Interest Paid, Excluding Capitalized Interest, Operating Activities 126K USD +2848%
Deferred Tax Assets, Valuation Allowance 67.7M USD +1.93%
Deferred Tax Assets, Gross 67.8M USD +1.99%
Operating Lease, Liability 456K USD +87.3%
Depreciation 27.6K USD -16.9%
Payments to Acquire Property, Plant, and Equipment 3.18K USD +71%
Lessee, Operating Lease, Liability, to be Paid 504K USD +67.8%
Property, Plant and Equipment, Gross 1.67M USD +1101%
Operating Lease, Liability, Current 182K USD +153%
Lessee, Operating Lease, Liability, to be Paid, Year Two 203K USD +90.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 215K USD +108%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -26.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 48.3K USD -15.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 85.9K USD -5.36%
Deferred Tax Assets, Operating Loss Carryforwards 41.6M USD +1.78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200K shares 0%
Unrecognized Tax Benefits 9.5M USD +47.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 47.5K USD +272%
Deferred Tax Assets, Net of Valuation Allowance 94.5K USD +89%
Share-based Payment Arrangement, Expense 8.32M USD +742%
Interest Expense 1.32M USD +173%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%